Tackling today’s top challenges of clinical research

Video
Conference|ARVO

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      David Hutton, executive editor of Ophthalmology Times®, sits down with Michael Watson, Vice President of OraNet to discuss this year’s most pressing challenges in clinical research: From the overburdening of sites with studies delayed by COVID to difficulties with staff retention and how holistic site support and patient solutions can provide enough to relief to keep projects on time and within budget.

      Newsletter

      Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

      Subscribe Now!
      Recent Videos
      A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
      A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
      Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
      How embracing opposition sends clinicians home from COPHy with more useful takeaways
      (Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      Related Content
      The FDA logo printed and embossed on cardstock. Concept image for FDA complete response letter, pharmaceutical ophthalmic CRL, eylea bayer and regeneron aflibercept. Image credit: ©Araki Illustrations – stock.adobe.com

      Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application

      Martin David Harp;Kassi Filkins;Hattie Hayes
      April 21st 2025
      Article

      The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

      PHOTON Results and Their Relation to DME Patients in Your Practice

      PHOTON Results and Their Relation to DME Patients in Your Practice

      July 25th 2024
      Podcast

      John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

      A young person with short androgynous hair sits in a waiting room, looking thoughtful. Concept image for racial groups in clinical trials and representation in studies. Image credit: ©wayhome.studio – stock.adobe.com

      DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials

      Lynda Charters
      April 17th 2025
      Article

      The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      July 24th 2024
      Podcast

      John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

      An image which shows a translucent head, with the eye, brain and optic nerve highlighted. Concept for brain-eye neurology neuroinflammation connection. Image credit: ©jitendra jadhav – stock.adobe.com

      Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104

      Sydney M Crago
      April 16th 2025
      Article

      In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

      Signage labaelling the Alcon Grieshaber AG facility in Schaffhausen, Switzerland. Image courtesy of Alcon.

      Alcon marks 110th anniversary of Grieshaber AG site in Switzerland

      Hattie Hayes
      April 15th 2025
      Article

      Alcon acquired the historic ophthalmic instrument company in 2000

      © 2025 MJH Life Sciences

      All rights reserved.